Shares of Galena Biopharma went into a tailspin on 18 March, plunging 21% after the company revealed the Securities and Exchange Commission (SEC) had opened an investigation into the firm and an outside investor relations company the biotech retained last year.
Galena's shares closed at $2.82 on 18 March, down 12.4%, or 40 cents.


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

